BACKGROUND AND PURPOSE: For locoregionally advanced HNSCC, chemoradiotherapy
with cisplatin or another platinum compound is considered as one of the standard treatment …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Background Intensification of chemoradiation for advanced head and neck squamous cell
carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

The management of squamous cell cancer of the head and neck (SCCHN) has become
increasingly complex, because combined interdisciplinary treatment approaches including …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …